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Abstract COPDis a commondisease anditsmajorrisk factor, cigarette smoking, hasbeenidentified.However, onlya
minorityof smokersdevelop clinicallyrelevantdisease.Although, the currentunderstandingofthepathogenesisincludes
an‘‘abnormal inflammation’’as a response to various noxious agents, its various pathways are not clear.Oxidative stress,
inflammation, tissue damage andtissuerepair (remodeling) arepartsofthe complexprocedureleading toCOPD.Thisis a
reviewofthe available literature concerning the‘‘susceptible’’smoker.An epidemiologicalmodel is discussed, putting em-
phasis onthetimingofthe exposureto cigarette smoke.There are evidences thatrespiratoryadenoviralinfectioninearly
life could be also an important factor. Differences in nutrition could also play a role in protecting against the oxidative
stress. Airway hyperresponsiveness failed to clarify the whole picture and is still open for debate.Genetic differences
are themost likelyexplanations to describe the‘‘susceptible’’smoker.However, the only well-establishedgenetic risk fac-
tor is the alpha-1-antitrypsin.Other candidate genes were reviewed, alpha-1-antichymotrypsin, blood group antigens,
vitamin-D bindingprotein, a2-macroglobulin, immunoglobulindeficiency, extracellular superoxide dismutase, secretory
leukocyte proteinase inhibitor, cathepsin G, tumor necrosis factor-a gene and others.Microsatellite DNA instability in
COPDcouldbe a useful tool to identify the locus of genetic alterations leading to COPD.Thus, in additionto exposure to
exogenous factors, hostfactors,mostlikely severalgenes, areinvolvedandaffect variouspathwaysofthepathogenesisof
COPD.r2002 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2002.1318, available online athttp://www.idealibrary.comon
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hyperresponsiveness.INTRODUCTION
It is unclear why only some smokers develop a clinically
signi¢cant chronic obstructive pulmonary disease
(COPD) (1^3).From a number of epidemiological studies,
it has become apparent that there are‘‘susceptible’’ smo-
kers that will develop COPD (1,3). Early pioneering and
in£uential ¢ndings by Fletcher showed that lung function
falls gradually over a lifetime, but in most non-smokers
and many smokers clinically signi¢cant air£ow obstruc-
tion never develops. In contrast, in ‘‘susceptible’’ people,
smoking causes irreversible obstructive changes (1).
However, the characteristics of such a susceptible in-
dividual are not known (4).The questions ‘‘is there a dis-
tinct group of susceptible smokers?’’ and ‘‘what is the
distribution (bimodal or unimodal) of susceptible’’ are ex-
tremely di⁄cult to be answered on the basis of the cur-
rent scienti¢c knowledge.
According to a newde¢nition developedby theGOLD
expert panel (5), COPD is a disease state characterized
by air£ow limitation that is not fully reversible. The air-Received12 September 2001, accepted in revised form 22 January 2002.
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abnormal in£ammatory response of the lungs to noxious
particles and gases.
It is likely that the answer to why only few smokers
develop COPD is within the phrase‘‘abnormal in£amma-
toryresponse to noxious agents’’of the de¢nition.COPD
is the result of an environmental insult and the response
of the host that is primarily genetically predetermined.
Another mystery concerning the pathogenesis of
COPD is why some patients develop predominantly par-
enchymal (emphysema) and other predominantly air-
ways disease (chronic bronchitis). This brings up the
possibility of sub-groups of ‘‘susceptible’’ individuals,
somewith primarily defects at the level of themajor air-
ways and others at the level of parenchyma. Are these
defects genetically determined? (4).
In ane¡ort toreview the current literature, a brief sum-
mary of the pathogenesis of the disease will be presented
¢rst.Then, the environmental insults (noxious agents) will
be discussed followedby the genetic risk factors.
PATHOGENESISOFCOPD: A
SYNOPSIS
Figure 1 is a schematic summary of the pathogenesis of
COPD. It is obvious that this scheme has several
FIG. 1. Schematic representation of the pathogenesis of COPD as result of host exposure to environmental risk factors. Abnormal
in£ammationmayplay signi¢cant role inthe pathogenesis (formore details, see text).
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mental animal studies and those fromhumans are limited
by the number of subjects, the selection of the patients,
the tissue and the method studied. Thus, there are a
number of missing links in the pathogenesis of COPD as
presented in Fig.1.
Oxidative stress
Cigarette smoke, the major environmental noxious
agent, contains abundant amounts of oxygen-based free
radicals, peroxides andperoxynitritewhich results in se-
vere oxidative stress in the lungs (6^9). The above sub-
stances by oxidizing cellular proteins, lipids, DNA bases,
enzymes and extracellular components as matrix col-
lagen and hyaluronic acid cause airway and parenchymal
injury (10,11).
One of the consequences of the oxidative stress is
chemotaxis, potent leukocyte adhesion and thus, initia-
tion of in£ammation. The recruitment of in£ammatory
cells such as activatedmacrophages and neutrophilsmay
also contribute to the oxidization by releasing speci¢c
enzymes (10^12).
Thus, cigarette smoke and local release of oxidants in-
itiate a vicious cycle thatmay promote an ‘‘abnormal’’ in-
£ammatory response. For example, oxidants activate
the transcription of the nuclear factor-kB (NF-kB),
Which promote genes of key in£ammatory players, such
as IL-8 and TNF-a (13,14). In addition, oxidants could
oxidize antiproteinases resulting in a reduction of the
antiproteinases shield and by activating matrix metallo-
proteinases to cause proteolysis (11,15).Oxidative injury
causes impairment in the barrier function of endothelial
and epithelial cells (16,17). Finally, if the oxidative stress issigni¢cant andprolonged, cellsmayundergo apoptosis or
direct necrosis (18,19).
In£ammation
Many cells have been reported to be involved in the
pathogenesis of COPD.However, their presence or acti-
vation in the a¡ected tissues or into £uids, such as spu-
tum or BAL, does not necessarily con¢rm their role in
the process of the development of the disease.The num-
ber of macrophages is increased in COPD (20). Further-
more, cigarette smoke activatesmacrophages to release
mediators, including IL-8, LTB4 and TNF-a (21). Thus,
macrophages may orchestrate the in£ammation in
COPD.
Neutrophils are themost studied cells in COPD; how-
ever, their role is not yet clear (22^24). Neutrophils
cause elastolysis by secreting neutrophil elastase, cathe-
psin G and proteinase 3 (25). In addition, neutrophil pro-
teinases are mucus stimulants. Recruitment of
neutrophils is the result of potent chemotaxis by IL-8,
LTB4, and increased adherence (Mac-1, E-selectin) (26).
Neutrophilic survival in therespiratory tract is increased
in COPD by the increase of cytokines, such as GM-CSF.
Although neutrophils are increased and/or activated in
other diseases, such as cystic ¢brosis, their elastolytic ef-
fect is not as prominent as in COPD.Thus, other factors
may be involved in promoting the elastolytic activity of
neutrophils in COPD (27).
T-lymphocytes are increased in lung parenchyma, and
in both peripheral and central airways in COPD (28,30).
Particularly, CD8+ cells are increased and may cause cy-
tolysis and apoptosis of alveolar epithelial cells (29,30).
Although there is an association of T-lymphocytes and
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(28,31) the role of T-cells in the pathogenesis of COPD is
not yet certain.
The role of eosinophils in COPD is obscure.There are
con£icting reports as far as their numbers in stable dis-
ease are concerned, butmost reports have shown an in-
crease during exacerbations (32^34).Furthermore, their
interaction with neutrophils and their degranulation is
under investigation.Recently, it has been shown that air-
way epithelial cells are important cells secreting in£am-
matory mediators. Cigarette smoke activates epithelial
cells to produceTNF-a and IL-8, thusmay initiate the ab-
normal in£ammatory response (35).Many in£ammatory
mediators could be involved in the pathogenesis of
COPD. Among them thebestknown are the lipidmedia-
tor LTB4 (21,33,35^37), the chemokine IL-8 and the cyto-
kine tumor necrosis factor-a (TNF-a). Other mediators
that have been reported in COPD are IL-5, GM-CSF,
TGF-b, EGF, the endothelin-1 (LT-1) and others (33,38^
40). The in£ammatory response in COPD may be up-
regulated by the abovemediators.
Tissue damage
The best-studied mechanism of tissue damage in COPD
is that of proteinase^antiproteinase (elastase/antielas-
tase) imbalance. Proteinases are enzymes that degrade
matrix proteins. Elastin is an important target, but col-
lagen, proteoglycans, laminin and ¢bronection are also
degraded (41^43).
The most potent proteinases are the neutrophil elas-
tase, cathepsin G and proteinase 3 and matrix metallo-
proteinases (44,45). Neutrophils are the major provider
of the above proteinases but other cells such as macro-
phages and airway epithelial cells could also contribute.FIG. 2. Overviewof risk factors for COPD.The elastolytic activity of proteinases is balanced by
the antiproteinases, such as a1-antitrypsin. A1- antitryp-
sin is the major endogenous tissue antiproteinase
(plasma/lung parenchyma) and SLPI is the major anti-
proteinase in the airways (41,46). A logical follow-on
from the imbalance in the proteinase/antiproteinase
system in favor of proteinases (Proteinolysis) (47) is
emphysema.
Tissue repair and ‘‘abnormal’’ remodeling
A tissue damage incidence is followedby an epithelial and
parenchymal repair process.This repair procedure is ex-
tremely complex and so far not fully understood. In the
airways, the repair (remodeling) process includes repair
of the tight junctions, cell migration, cell di¡erentiation
andmetaplasia, mitosis and hyperplasia of basal cells and
mitotic redi¡erentiation among others (48). It has been
shown that smoke impairs lung repair mechanisms
(49,50) and disrupts procedures that are able to restore
tissue structure. This may lead to peribronchial ¢brosis
and narrowing, particularly at the site of small airways.
Fibronectin and TGF-b produced by the epithelial cells
are involved in the normal repair processes but may be
an excess of those factors that cause ¢brosis and abnor-
mal remodeling (39,51).
RISKFACTORS
Risk factors for COPD include both environmental ex-
posures and host factors, and the disease usually devel-
ops from an interaction between the two (5). Figure 2
provides a schematic classi¢cation of risk factors for
COPD.
FIG. 3. Epidemiologicalmodel of COPD during the life cycles.
Fromtop: during pregnancy (gray area); during lung growth (0^
20 years) (gray area); during the plateau phase (20^40 years)
(gray area); during lung function decline (40 years) (gray area).
FEV1: forcedexpiratory volumeinone second.Arrow (m): Birth,
(gray area): life cycle under discussion. [Modi¢ed from: Rijcken
and Britton (3) with permission].
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Cigarette smoke (epidemiologicalmodel of COPD)
Among the risk factors that have been related to COPD,
cigarette smoke is the best studied and is a consistent
¢nding in numerous studies (1,52,53). Thus, all recent
guidelines of COPD considered cigarette smoking the
best-established risk factor for the development of the
disease (54,55). In addition, passive cigarette smoking
was related to chronic cough and sputum and is also a
candidate risk factor for the development of air£ow lim-
itation (53,56,57).
However, from the above epidemiological studies, it is
apparent that not all smokers develop clinically impor-
tant COPD, and second that there is not a direct dose^
e¡ect relationship. A passive smoker may develop the
disease,whereas a heavy smokermaynot.Theseobserva-
tions lead to the hypothesis of the‘‘susceptible’’ smoker.
The epidemiological ‘‘longitudinal’’ studies suggested
that amore important factor than the dose (pack/years)
is the timing of the exposure to cigarette smoke (58,59).
This was summarized in an epidemiological model of
COPD risk shown in Fig. 3. Although COPD is a disease
ofmiddle/late adult life, events thatoccurduring early life
mayplay a signi¢cantrole.For example, active or passive
smoking during adulthoodwhen the lungs are developed
may position the individual smoker to the lower part of
the‘‘horserace’’and thus,makinghim‘‘susceptible’’ to de-
velop COPD (Fig. 3).Furthermore, an additional e¡ect in
the maturation of the respiratory system could be the
maternal smoking during pregnancy [Fig. 3 (a)]. Finally,
the thirdphase of adult lifewhere the susceptible smoker
is characterized by a rapid decline in FEV1 is well known
[Fig. 3 (c)]. Thus, the timing of exposure to cigarette
smoke is crucial and may have di¡erent and/or addictive
e¡ects. Cigarette smoke could operate before birth
(lower initial lung volume), during growth (lower maxi-
mal attained volume), plateau phase (earlier start of de-
cline) and during the late phase with an accelerated
decline (1,60,61).
Noxious agents
A combination of exogenous risk factors could be an al-
ternative hypothesis of the ‘‘susceptible’’ smokers. Expo-
sure to a mixture of known noxious agents, such as
active plus passive smoking, and environmental pollution
and occupational pollution could cause COPD.However,
the current data do not support the hypothesis of com-
bination of risk factor as the basis of the ‘‘susceptible’’
smoker (3).
Respiratoryinfections
There are studies that suggest a link between severe
childhood respiratory infections and COPD in adult life(62). However, this association is rather weak because it
is not retrospectively easy to exclude the possibility that
these infections are the result of lung function impair-
ment and not the cause. Nevertheless, viral infections
may directly contribute to the development of COPD
by incorporating viral DNA into the airway cells. This
could alter their geneticmaterial and thus their response
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creased levels of adenoviral DNA have been found in
COPD patient in comparison with the control ones (63).
Furthermore, incorporation of adenoviral DNA in ani-
mal epithelial cells has been shown to amplify the in£am-
matory response, when exposed to cigarette smoke
(64,65).Therefore, a possible scenario couldbe that ‘‘sus-
ceptible’’ smokers are the ones with an early-life viral in-
fection leading to an excessive load of adenoviral DNA in
the epithelial cells. Those cells then can orchestrate an
‘‘abnormal’’ in£ammatory response to cigarette smoke.
However, other investigators had not duplicated these
results in human.
The British hypothesis (chronic mucus hypersecretion)
supported that goblet cell hyperplasia in peripheral air-
ways occurs in smokers (1,62,66) and therefore, predis-
poses them to respiratory infection. Recent results
from the lung health study, in 5887 smokers, conducted
by Kanner showed that smoking and lower respiratory
illnesses (LRI) had an interactive e¡ect on FEV1in people
with mild COPD while in smokers frequent respiratory
infections may in£uence the long-term prognosis of the
disease (67).
Nutrition
Nutritional elements with antioxidant properties could
play a role in the developmentofCOPD. Suchdietary fac-
tors are the antioxidant vitamins C and E, magnesium
and ¢sh oils. In addition to the endogenous enzymatic
antioxidant systems, the above nutritional antioxidants
(vitamins C and E) may enhance the host defense against
the oxidative stress of cigarette smoke. Fish oil contains
highlypolyunsaturatedo-3 fatty acids that act as compe-
titive inhibitors of arachidonic acidmetabolism.Thus, ¢sh
oil could down-regulate the in£ammatory potency of li-
pid mediators, as LTB4, and protect against COPD
(68,69). It is possible that smokers who develop COPD
have a de¢cit of the above nutritional element in their
diet. However, this hypothesis is not supported by long-
itudinal studies (70) and couldnot explain thewhole pro-
blem, since there are so many confounding factors
between diet and cigarette smoking (alcohol intake, etc).
Host factors
Airway hyperresponsiveness (Dutch hypothesis)
The relationship among increased airway reactivity, ato-
py and the development of COPD was ¢rst proposed by
Orie et al. in 1961 (71). In other words, smokers with hy-
perreactive airways could be the ‘‘susceptible’’ ones that
will develop COPD. This hypothesis is still open for de-
bate, because it is not clear, if hyperresponsiveness is
the cause or the e¡ect of the decrease in FEV1 in smo-
kers. Airways reactivity and atopy are complexdisordersrelated to a numberof genetic andenvironmental factors
leading to allergic in£ammation (asthma).This in£amma-
tion, however, has been shown recently to be di¡erent
from that caused by cigarette smoke (72). In addition,
other investigators suggested that hyperresponsiveness
seen in smokers is the result of abnormal geometry of
the airways (73,74). In addition, the majority of the stu-
dies investigating FEV1decline have tested airways reac-
tivity at the end of the study (after the initiation of
smoking) (73,74) and only few at the beginning (75,76).
Recently, two studies thatreported association of hyper-
responsiveness in sub-groups of smokers lacking statisti-
cal testing of the smoking strata (77,78).When the study
was performed (79,80), the association of reactivity and
smoking was not found signi¢cant.
Finally, another argument against the Dutch hypoth-
esis is the observation that only approximately 12% of
the patients with COPD showed increased responsive-
ness. If theDutchhypothesiswas completed, thenhyper-
responsiveness would be the feature of most of the
COPD. In conclusion, theDutch hypothesis failed to clar-
ify the issue of ‘susceptible’’ smoker and is still open for
debate.
Genes
It ismost likely that the answer to themystery whyonly
few smokers develop COPD is found in the ocean of ge-
netics. Familiar aggregation has been reported in COPD
(81,82) but other confounding factors are di⁄cult to ex-
clude. In addition,COPD is a disease ofmiddle age andby
that time parents or grandparents are rarely alive in or-
der to perform a classical hereditary study. Further-
more, it is most likely that many genetic factors
interact to increase or decrease the risk to develop
COPD.Thus,Mendel’s laws of inheritance of ‘‘susceptibil-
ity’’ to cigarette smoke could be ruled out (83).
Alpha-1-antitrypsin: Until now, the only established ge-
netic risk factor for COPD is homozygosity of a1-anti-
trypsin (a1-At) gene. The ¢rst study was performed by
Laurell and Eriksson in the1960s. A1-antitrypsin is a po-
tent antiprotease produced by the liver. Homozygous Z
patients have a very low a1-ATand show rapid decline in
FEV1 even without smoking (84,85). In smokers with a1-
AT homozygous, COPD is developed at a younger age
(86,87). However, this homozygous state is rare in the
general population (1in 5000 live-births) (88) and there-
fore, genetic risk factor can explain less than 1% of the
COPD.
Furthermore, numerous investigations have assessed
the risk of heterozyous genotypes. The common gene
variants are M, S and Z and their frequency is reported
0.93, 0.05, and 0.02, respectively.MM genotype is consid-
ered normal. MS show mild reduction in a1-AT(B80%
normal), MZ has lower a1-AT (B60% normal), SZ even
lower (B40% normal) and ZZ (o15% normal). A large
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genotype to thosewithMM and found no signi¢cant dif-
ference in pulmonary function or symptoms in non-smo-
kers (83). In smokers there are con£icting results. It was
shown thatMZ smokers had greater loss of elastic recoil
than MM smokers (89) or rapid decline in FEV1 (90).
Furthermore, in addition to the mutation that a¡ect
the level of serum a1-AT, other mutations have been de-
scribed that a¡ect its function (91). One of those is the
mutation in the 3’ region of a1-AT gene (92,93). Never-
theless, this mutation is not speci¢c for COPD since it
has been found in bronchiectasis as well (92,93). Other
investigations had proposed that the 3’ mutation allele
could be in disequilibrium with an a1-antichymotrypsin
(a1-ACT) de¢ciency allele (94).Other investigations sug-
gested that the 3’mutation could a¡ect the acute-phase
response leading to an inadequate up-regulation of a1-AT
during acute in£ammation (95). This could be also true
during the acute oxidative stress of cigarette smoking.
Thus, not only the level but also the structure and func-
tion of a1-AT is genetically predetermined and could pre-
dispose to COPD in smokers.
Candidate genes
Alpha-1-antichymotrypsin (a1-ACT) is acute-phase reac-
tant with antiprotease properties produced by the liver.
A1-ACT de¢ciency is present only in 1% of Swedish gen-
eral population transmitted by the autosomal dominant
inheritance pattern (96). Two mutations in the a1-ACT
gene have been associated with decreased a1-ACT ser-
um level (97), but the relationship of low a1-ACTor its
defective functionwith COPD is not clear.
Vitamin-D-binding protein (VDBP) is a protein serrated
by the liver that is able to vitamin D, endotoxin and to
act as macrophage-activating factor or chemotractant
enhancer of C5a (98,99).Thus, it can regulate the in£am-
matory response or diminish antioxidative capacity of
the host. A decrease frequency of 2-2 genotype ofVDBP
was reported in COPD patients (100) but this was not
replicated (101).
Alpha2-macroglobulin (a2-macroglobulin) is a protease
inhibitor and its serum de¢ciency is rare. A2-macroglo-
bulin gene is located on chromosome12 and its sequence
has been identi¢ed. However, there are only case re-
ports ofpatientswithCOPD and a2-macroglobulinpoly-
morphism (102).
Immunoglobulin de¢ciency for selective IgA has been
found to segregate with COPD in a three-generation
pedigree (103). Other investigators studied the role of
IgA or IgG de¢ciency as a etiologies of COPD in relation
with recurrent infections (104,105).
Extracellular superoxide dismutase (EC-SOD) is an im-
portant extracellular antioxidant enzyme in the lung
and attenuates tissue damage produced by cigarette
smoke’s oxygen radicals. A polymorphism in the EC-SODgenehasbeen reported in 2% of general population
(106). If this variant of the gene plays a role in the patho-
genesis of COPD is not known.
Secretory leukocyte proteinase inhibitor (SLPI) is pro-
duced by the airway epithelial cells and is able to inhibit
neutrophil elastase (107) and considered the potent anti-
proteinase of the airways. Polymorphism of the SLPI
gene has been detectedbut nomutations (108).This sug-
gests that structural alterations in SLPI may not be in-
volved in the pathogenesis of COPD.
Othercandidate genes
A mutation in the cathepsin G gene, a serine protease,
was found but it was not associated with COPD (109).
In addition, a relationship was reported between poly-
morphism in the gene for microsomal epoxide hydrolase
and susceptibility to emphysema (110). Recently, poly-
morphism of tumor necrosis factor-a gene was investi-
gated in chronic bronchitis (111).
‘‘Geneticmarkers’’
Blood group antigens. An association between the ABO
locus and COPD was reported and the type A blood
group was associated with impaired lung function (112).
Others failed to con¢rm any relationship between ABO
alleles and pulmonary function (113,114).
Although the ABO antigens in the respiratory tract
secretions may have a protective role (101,115) and could
be the defect in susceptible smoker, these observations
have not been duplicated in air£ow obstruction
(113,114,116). Similarly, the Lewisblood systemhadbeen in-
vestigated in air£ow limitation and itwas shown that Le-
wis-negative subjects were at greater risk (117). Blood
group antigens have been associated with recurrent in-
fections that may lead to COPD. However, the role of
ABO, Lewis and secretor genes remain unclear in the
pathogensis of COPD.
Human leukocyte antigen locus (HLA). A signi¢cant de-
crease of HLA-Bw16 allele was found in COPD patient
with a low FEV1value and an increase in HLA-B7 antigen
(101).However, it is not clear whether these associations
due to variations in HLA genes themselves or if they ex-
press susceptibility to COPD.
Cytochrome P4501A1. A recent study reported that the
high-activity allele of CYP1A1 was associated with sus-
ceptibility to centrilobular emphysema and lung cancer
but this was not linked to cancer alone in the absence of
emphysema (118).
Cystic ¢brosis transmembrane regulator (CFTR). The
abovemutation has been examined in chronic bronchitis
and found that none of the known mutation of CFTR is
associatedwith COPD (119).
Microsatellite DNA instability (MSI) in COPD. Microsatel-
lites of DNA are short tandem nucleotide repeats
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DNA instability has been correlated with high muta-
tional rates (120). Thus, MSI could be a useful technique
to identify locus of potential altered genes.This method
hadbeen applied in sputum cells of COPD patients and it
was shown that this defect is a detectable phenomenon
(121).
Recently, sputum cells from groups of smokers with
and without COPD were tested for MSI (122). Both
groups had similar smoking history.MSI was detected in
24% of COPD patients but in none of the non-COPD
smokers.These results indicated that MSI could be part
of the complex genetic basis of COPD and could be a
marker of genetic alteration caused by smoking leading
to COPD.Thus, MSI may be an index of the ‘‘susceptible’’
smoker (122).However, more studies are needed to ver-
ify these results.
CONCLUSIONS
In conclusion, theremust be a number of host factor ge-
netically predetermined that characterize the ‘‘suscepti-
ble’’ smoker. It is apparent that several genes are involved
and this area of the pathogenesis (123) of the disease ur-
gently needsmore exploration. Excellent reviews on the
genetic risk factors for COPD are provided by Sandford
et al. (83) and Barnes (124).
FUTUREPERSPECTIVES
It would be revolutionary if new genes could be discov-
ered thatexplain thepredisposition of ‘‘susceptible’’ smo-
ker to develop COPD. Linkage analysis in families of
COPDpatients, usingpolymorphicmarkers could identi-
fy chromosomal locations harboring genes involved in
the pathogenesis of the disease.
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